London, UK; Brentwood, TN, US: 27 November 2006 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces the transfer of market rights for Digitalis Antidot® from Roche to Protherics, with the intention of replacing Roche’s Digitalis Antidot® in the market with Protherics’ own digitalis antidote DigiFabTM from early 2007.
